N-Acetyl Selank Amidate: Discovery and Research History

Introduction

N-Acetyl Selank Amidate occupies a specific position in a research lineage that spans more than five decades and two countries of origin. The chain begins with the 1970 discovery of tuftsin at Tufts University in Boston, continues through the systematic peptide-extension chemistry conducted at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow during the 1990s, and culminates in the regulatory registration of the parent compound Selank in Russia and the subsequent development of terminally modified research variants. This article traces that history based on published primary literature and peer-reviewed reviews.

Discovery Period: Tuftsin (1970–1980s)

The direct structural ancestor of Selank is tuftsin, the tetrapeptide Thr-Lys-Pro-Arg. Tuftsin was first described by Najjar and Nishioka in 1970 in a report published in Nature, identifying the peptide as a phagocytosis-stimulating factor residing in the Fc domain of the immunoglobulin G heavy chain [1]. The name "tuftsin" was coined in reference to Tufts University, where the discovery was made.

Tuftsin is liberated from its parent immunoglobulin by the sequential action of two enzymes: a spleen endocarboxypeptidase that cleaves the C-terminal end of the precursor leukokinin, and a membrane-associated leukokininase present on neutrophils, monocytes, and macrophages [1]. In free form, tuftsin stimulates phagocytosis, chemotaxis, and bactericidal activity in mononuclear phagocytes, and was subsequently characterized as possessing broader immunomodulatory properties including modulation of macrophage activation and T-lymphocyte responses.

During the 1970s and 1980s, extensive structure-activity work on tuftsin analogs was conducted by multiple research groups seeking to establish the pharmacophoric determinants of its immunological activity. These studies documented which residues tolerated substitution, which were essential for receptor engagement, and what structural modifications altered the spectrum of immunological effects — providing both the conceptual and synthetic foundation for subsequent neuropeptide derivatization programs.

Early Research: The Institute of Molecular Genetics Program (1990s–2000s)

The development of Selank from the tuftsin scaffold is attributed to research groups at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow, with principal contributors including Nikolay Myasoedov and Lyudmila Andreeva. Working in collaboration with the V. V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences, these groups investigated whether extending the tuftsin tetrapeptide at its C-terminus could yield analogs with improved metabolic stability and distinct CNS pharmacological profiles.

The rationale was precise: native tuftsin undergoes rapid degradation by enzymatic hydrolysis in plasma, limiting its in vivo residence time and constraining pharmacological study. By appending a C-terminal Pro-Gly-Pro tripeptide to the Thr-Lys-Pro-Arg sequence, the researchers produced the heptapeptide that would be registered under the International Nonproprietary Name (INN) "Selank." The extended sequence exhibited substantially prolonged residence time relative to native tuftsin in early rodent studies, with pharmacological effects in behavioral assays lasting several hours after a single administration [2] — a meaningful advance over the rapidly-cleared parent structure.

Peer-reviewed publications characterizing Selank's behavioral and neurochemical properties began appearing in the early 2000s. Myasoedov, Andreeva, and colleagues described Selank and related short tuftsin-family peptides as regulators of adaptive behavior under stress in rodent models [2], establishing the foundational behavioral pharmacology that subsequent mechanistic studies sought to explain at the molecular level.

A pivotal mechanistic finding emerged from Semenova and colleagues in 2001, who reported that Selank dose-dependently inhibited the enzymatic hydrolysis of enkephalin in plasma-derived preparations, with activity exceeding that of reference enkephalinase inhibitors [3]. This observation — that a tuftsin-derived heptapeptide could interact with the endogenous opioid peptide degradation system — opened a parallel line of inquiry into Selank's mechanisms beyond pure immunology, and established a GABAergic/enkephalinergic framework for understanding behavioral effects that proved productive for the subsequent two decades of investigation.

Expanding the Research Landscape (2000s–2010s)

Throughout the 2000s and 2010s, a sustained program at the Institute of Molecular Genetics, led by investigators including Shadrina, Slominsky, Limborska, and Kolomin, expanded the mechanistic characterization of Selank using molecular biology tools unavailable to the first generation of peptide researchers. Gene expression profiling by quantitative PCR allowed the group to characterize Selank's effects on transcriptional programs in neural and immune tissue with substantially greater resolution than behavioral assays alone.

Kolomin and colleagues (2008) reported that intranasal administration of Selank was associated with alterations in Bdnf mRNA and BDNF protein levels in the rat hippocampus [4], extending the mechanistic picture beyond receptor pharmacology to include neurotrophic signaling — a finding that would inform subsequent interest in Selank's effects on CNS circuitry. Studies published in Regulatory Peptides in 2011 examined the expression of 84 inflammatory genes in mouse spleen tissue following Selank administration [5], and in vivo frontal cortex GABAergic gene expression was reported in Frontiers in Pharmacology in 2016 [6], collectively establishing Selank's documented reach across both CNS and peripheral immune tissue.

The GABAergic pharmacology received independent characterization from research groups at the V. V. Zakusov Research Institute of Pharmacology, including Kolik, Konstantinopolsky, and Nadorova. Their work identifying strain-specific receptor binding and behavioral responses — particularly the marked pharmacological sensitivity of the high-anxiety BALB/c strain compared to C57BL/6 mice [7] — provided important design guidance for subsequent rodent model research using this compound class.

The immunological lineage of the compound was explored through cytokine profiling during experimental stress. A 2020 publication reported attenuation of pro-inflammatory cytokine concentrations (IL-1β, IL-6, TNF-α, TGF-β1) in socially stressed rodents receiving Selank [8], consistent with the tuftsin structural heritage and with the splenic gene expression data from earlier years.

Regulatory Milestones

Selank received regulatory registration in the Russian Federation as a pharmaceutical product for anxiety disorders and neurasthenia — a milestone documented in the peer-reviewed literature by Deigin and colleagues (2022) in their review of peptide biopharmaceutical development in Russia [9]. The nasal drop formulation was approved, making Selank one of a small cohort of peptide-based neuroactive drugs to achieve full pharmaceutical registration anywhere in the world, and placing the Institute of Molecular Genetics program among the handful of basic-research neuropeptide programs that progressed to regulatory completion.

That review situated Selank within a broader program of neuropeptide drug development that had its origins in Soviet-era basic research institutes and transitioned through the post-Soviet period into formal pharmaceutical registration, alongside Semax (a Melanocyte-stimulating hormone fragment-based compound) and other compounds. A comparable institutional trajectory characterizes Epithalon, another Russian-origin research peptide developed at the St. Petersburg Institute of Bioregulation, which similarly progressed from Soviet-era laboratory work to a documented published research record without Western regulatory approval. The existence of a registered pharmaceutical product in the Selank structural class is documented in peer-reviewed pharmacology literature and represents the deepest institutional validation of the compound's research program.

N-Acetyl Selank Amidate, as a distinct chemical entity incorporating the dual terminal modification, has not been the subject of independent regulatory filings with the United States FDA, the European Medicines Agency, or other major Western regulatory authorities. No clinical trial registrations for the acetylated/amidated variant have been identified in ClinicalTrials.gov or equivalent registries. The regulatory history of the parent Selank program in Russia constitutes the closest institutional precedent for this compound class and reflects the research investment underlying the structural family.

Current Research Landscape

The most recent indexed English-language publications on Selank continued the opioid pharmacology line of investigation, with a 2022 study from the V. V. Zakusov Research Institute of Pharmacology examining Selank's effects in a naloxone-precipitated morphine withdrawal model and reporting a 39.6% reduction in the composite withdrawal index in outbred rats [10]. This work extended the enkephalin-degrading enzyme inhibition hypothesis — established over two decades earlier — into a translational model with direct relevance to opioid dependence pharmacology research, and demonstrates that the Selank research program remains an active contributor to the indexed literature.

N-Acetyl Selank Amidate as a distinct compound is represented in the NIH PubChem database (CID 133082488) with the molecular formula C₃₅H₅₉N₁₁O₁₀, confirming its structural registration. Direct pharmacological characterization studies for the acetylated/amidated variant — including receptor binding assays, plasma half-life measurements, and behavioral studies using the modified compound specifically — represent a natural next step for the research community building on the parent-compound literature. Research-grade material with batch-level purity documentation is available via the N-Acetyl Selank Amidate product page.

The terminal modification strategy — N-terminal acetylation and C-terminal amidation — is a well-established approach in peptide research for conferring resistance to exopeptidase-mediated degradation and is documented to extend plasma half-life across multiple research peptide scaffolds. Its application to Selank follows a pattern with clear precedent in the broader field; direct experimental confirmation of the modifications' effects on the Selank pharmacological profile represents an area of ongoing research opportunity.

The Selank research program as a whole remains concentrated at Russian research institutions, with English-language publications representing translated and internationally published work from the original Russian-language research record. Sources published in Eksperimentalnaya i Klinicheskaya Farmakologiya (Experimental and Clinical Pharmacology) and Zhurnal Vysshei Nervnoi Deyatelnosti (Journal of Higher Nervous Activity) constitute the main venues for original-language reporting from the groups involved.

For mechanistic detail, see N-Acetyl Selank Amidate: Mechanism of Action. For a summary of individual published studies, see N-Acetyl Selank Amidate: Published Research.

References

1. Najjar VA, Nishioka K. "Tuftsin": a natural phagocytosis stimulating peptide. Nature. 1970;228(5272):672-3. PMID: 4116440. DOI: 10.1038/228672a0.

2. Myasoedov NF, Andreeva LA, Samonina GE, Kamenskiy AA. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Zhurnal Vysshei Nervnoi Deyatelnosti Imeni I P Pavlova. 2004;54(1):76-83. PMID: 14969422.

3. Semenova TP, Kozlovskaya MM, Zuikov AV, Kozlovskiy II, Zuikov PV, Lygalov AV. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2001;64(4):15-7. PMID: 11550013.

4. Kolomin T, Shadrina M, Agniullin Y, Shram S, Slominskii P, Limborska S, et al. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-3. PMID: 18841804. DOI: 10.1134/S0012496608040066.

5. Kolomin T, Shadrina M, Slominsky P, Limborska S, Myasoedov N. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18-23. PMID: 21609736. DOI: 10.1016/j.regpep.2011.05.001.

6. Filatova EV, Shadrina MI, Slominsky PA, Boldyrev AA, Lyapina LA, Andreeva LA, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;6:317. PMID: 26793110. DOI: 10.3389/fphar.2015.00317. PMC: PMC4757669.

7. Kolik LG, Nadorova AV, Konstantinopolsky MA. Comparison of Pharmacological Effects of Heptapeptide Selank After Intranasal and Intraperitoneal Administration to BALB/c and C57BL/6 Mice. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2018;81(3):3-8. PMID: 29787664.

8. Kolik LG, Nadorova AV, Konstantinopolsky MA. The Influence of Selank on the Level of Cytokines Under the Conditions of "Social" Stress. Eksperimentalnaya i Klinicheskaya Farmakologiya. 2020;83(6):3-7. PMID: 32621722.

9. Deigin VI, Poluektova EA, Beniashvili AG, Kozin SA, Poluektov YM. Development of Peptide Biopharmaceuticals in Russia. Pharmaceutics. 2022;14(4):716. PMID: 35456550. DOI: 10.3390/pharmaceutics14040716. PMC: PMC9030433.

10. Konstantinopolsky MA, Chernyakova IV, Kolik LG. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bull Exp Biol Med. 2022;173(6):722-726. PMID: 36322304. DOI: 10.1007/s10517-022-05624-x.